Company Overview
Ridgetech, Inc. operates as a wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. It operates in two segments, Offline Wholesale and Online Platform. The company engages in the offline and online wholesale distribution of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicine, personal and family care products, and medical devices, as well as convenience products comprising consumable, seasonal, and promotional items. It also distributes other healthcare products, such as health food, cosmetics, and daily necessities. The company was formerly known as China Jo-Jo Drugstores, Inc. and changed its name to Ridgetech, Inc. in February 2024. Ridgetech, Inc. is headquartered in Hangzhou, China.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $132.16M (+10.2% YoY); net profit $-1.25M.
- Trailing 12 Months Year-on-year growth — revenue +21.4%, earnings -112.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.21% |
| 1 Year: | 21.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -112.27% |
Stock Price Performance
| 1 Year: | -99.54% |
| 6 Months: | -99.62% |
| 3 Months: | -40.00% |
| 1 Month: | +16.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.30 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 99.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RDGT Ridgetech, Inc. PHARMA | 0.87 | -0.05 | $782.05K | 0.00% | -4.54% | -3.55% | 3.21% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 120.20M | 123.99M | 119.97M | 132.16M |
| Cost of Revenue | - | 116.60M | 119.12M | 116.13M | 127.41M |
| Gross Profit | - | 3.60M | 4.88M | 3.84M | 4.75M |
| Operating Expenses | - | 16.76M | 4.28M | 4.87M | 6.62M |
| Operating Income | - | -13.16M | 596.08K | -1.04M | -1.87M |
| EBITDA | - | -12.44M | 4.56M | 5.07M | -918.76K |
| Interest Expense | - | 65.85K | 0 | 0 | 67.07K |
| Pretax Income | - | -15.44M | -827.07K | -950.66K | -1.35M |
| Tax Provision | - | 394.54K | -41.36K | 503.52K | -99.10K |
| Net Income | - | -21.14M | -4.23M | 10.19M | -1.25M |
| Diluted EPS | - | -6,219.00 | -439.78 | 275.87 | -17.21 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 90.97M | 95.06M | 64.48M | 69.03M |
| Current Assets | - | 64.48M | 69.68M | 59.71M | 64.56M |
| Cash & Equivalents | - | 18.81M | 2.30M | 12.78M | 17.91M |
| Inventory | - | 15.31M | 9.08M | 9.76M | 8.26M |
| Receivables | - | 14.10M | 6.01M | 27.78M | 32.47M |
| Total Liabilities | - | 74.30M | 80.76M | 34.85M | 28.25M |
| Current Liabilities | - | 66.54M | 74.36M | 34.36M | 27.89M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 42.16M | 6.59M | 10.39M | 22.67K |
| Total Equity | - | 18.01M | 15.64M | 29.64M | 40.78M |
| Shares Outstanding | - | 7.90K | 11.62K | 39.03K | 887.27K |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -3.28M | -3.16M | 1.25M | -1.39M |
| Investing Cash Flow | - | -316.10K | -2.04M | -18.14M | -449 |
| Financing Cash Flow | - | 2.37M | 8.00M | 1.51M | -29.71K |
| Capital Expenditure | - | -311.72K | -923.64K | -615.27K | -449 |
| Free Cash Flow | - | -3.60M | -4.08M | 632.50K | -1.39M |
| Net Change in Cash | - | -1.23M | 2.81M | -15.38M | -1.42M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 3.0% | 3.9% | 3.2% | 3.6% |
| Operating Margin % | - | -11.0% | 0.5% | -0.9% | -1.4% |
| Net Margin % | - | -17.6% | -3.4% | 8.5% | -0.9% |
| ROE % | - | -117.3% | -27.1% | 34.4% | -3.1% |
| ROCE % | - | -53.9% | 2.9% | -3.4% | -4.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 2.49% | 90.30K | $82.17K |
| 2 | Virtu Financial LLC | 0.79% | 28.78K | $26.19K |
| 3 | UBS Group AG | 0.22% | 8.07K | $7.34K |
| 4 | Harbour Investments, Inc. | - | 1 | $0 |
| 5 | HHLR Advisors, LTD | - | 136 | $123 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RDGT
Ridgetech (NASDAQ: RDGT) signs $184,720,213 at-the-market equity deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPcjdpeDNBTU4yZU9GRGtmcTUxLUEzSElmWWVNMldvVy0zSmZLSC1mYmdreUhralJkNXNJVHBDR3NJcGI1amZlVVdIT3puODZFOFFrM3RPVDdsZVNoTDZrQkhxbENlMzRiVWVLRGwtdkpUb3oybXJXYWFqTDdCVTRPUTVTaGxibDEyaVVIdF…
$RDGT stock is up 16% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPdUk4bmFXcnVOTzhMQ1N4TDNKUW1MUy1Ma0FGaUc4Z3A1SF9hTEx3Q0V6YjAzN2wyd0g5YURyRlVWdDlZU2ZiclIwSktwY29XTzdQMlQyQU84ei11SjdSclFuUGJtNzlqVVdNSGRwS0tzNkc1bjJfc3NxbG5BWjQ1ZmgzaXdIN0hQMy1Hcm…
RDGT|Ridgetech Inc|Price:0.908|Chg%:+0.007 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1TdFNXRjdNMm4teTBFdUJObk5PQTRsZlVhQmZ2SDRHR2NnVm43aFJfa3JyQWYzU3E0amtFOTZ0dHY4cWZYemtXMm4wek1YTnlmLVlvQ3JDblJkY3ZqUzZnOXg4SDNISy0weThoRTB3?oc=5" target="_blank">RDGT|Ridgetech Inc|…
RDGT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE11bXlHVFpvVEVjYklPcllVLXl4cl9nMEpNaUYySDJjS0R6b1g4bm1hMFM0UEpiTjlxNTc3ZG16QlVTc2E1ZlE?oc=5" target="_blank">RDGT</a> <font color="#6f6f6f">Finviz</font>…
Ridgepost Capital (RDGT) Stock Rallies As Margin Pressure Clouds Fee Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZ29PbkFCbGE4djJwZDJqMmxkRGFqbEhVMTBnRjJTbFNPVVkyS2FFSDRqVW5sNW9wVFIzcDdaVTlST3dwblBqTlU2QnBCNTRYTzZlbTByN01YNk5qSkZHMjBBQW1OcV9yZVFuWVd1b3lxNXdNSkFZRElCY0ItZjdnSlVYUVI0MWstUVB4eH…
Ridgetech, Inc. Announces 1-for-150 Reverse Share Split - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQV0phcDF2cnBhSXBzOWhvaDRsaUtKaGg2a0c0QXllRlFXaVpVcWdjbW9Ja014RWY0NVZlbTEwNG9OLXBoaHFDTU8wVzlib1hfQUM1U19BVGJDSEJQeF8tZUlscWgyRnN5dmdNRmFqaWpJa0d2a2hSaGhIeXZfNGRtZHR1V1JZcUlSdFo0TX…
RDGT — Frequently Asked Questions
What is the current share price of Ridgetech, Inc. (RDGT)?
As of 2026-09-19 21:16 PDT, Ridgetech, Inc. (RDGT) trades at $0.87 on NasdaqCM. Its 52-week range is $0.71 to $760.50.
What is the market capitalisation of RDGT?
Ridgetech, Inc. (RDGT) has a market capitalisation of $782.05K on NasdaqCM.
What is the P/E ratio of RDGT?
RDGT trades at a trailing price-to-earnings (P/E) ratio of -0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.02.
What is the return on equity (ROE) of RDGT?
RDGT has a return on equity (ROE) of -3.55%. Its return on capital employed (ROCE) is -4.54%.
Is RDGT a good stock to buy?
This page provides a data-driven analysis of Ridgetech, Inc. (RDGT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.